Purpose: To investigate the association between dry eye (DE) and insomnia symptom severity. Methods: Cross-sectional study of 187 individuals seen in the Miami Veterans Affairs eye clinic. An evaluation was performed consisting of questionnaires regarding insomnia (insomnia severity index [ISI]) and DE symptoms, including ocular pain, followed by a comprehensive ocular surface examination. Using a two-step cluster analysis based on intensity ratings of ocular pain, the patient population was divided into two groups (high and low ocular pain groups: HOP and LOP). A control group was ascertained at the same time from the same clinic as defined by no symptoms of DE (Dry Eye Questionnaire 5 [DEQ5], ,6). The main outcome measure was the frequency of moderate or greater insomnia in the DE groups. Results: The mean age of the study sample was 63 years, and 93% were male. All insomnia complaints were rated higher in the HOP group compared with the LOP and control groups (P,0.0005). Most (61%) individuals in the HOP group experienced insomnia of at least moderate severity (ISI$15) compared with the LOP (41%) and control groups (18%) (P,0.0005). Black race (odds ratio [OR], 2.7; 95% confidence interval [CI], 1.2-6.0; P¼0.02), depression severity (OR, 1.2; 95% CI, 1.1-1.3; P,0.0005), and DE symptom severity (DEQ5; OR, 1.1; 95% CI, 1.01-1.2; P¼0.03) were significantly associated with clinical insomnia (ISI$15) after controlling for potential confounders.
D
ry eye (DE) is a common condition reported to affect 15% of the general population. 1 It is a heterogeneous disorder that can manifest with symptoms (dysesthesias, pain, visual complaints) and ocular surface signs (abnormal tear production, evaporation, increased osmolarity, damage to the ocular surface). 2 The morbidity of DE comes from its symptoms, which decrease the quality of life by affecting physical function and mental health. 3 Traditionally, DE has been subcategorized based on the findings of aqueous or evaporative deficiency. 2 Newer data suggest that somatosensory dysfunction may be another component of DE that underlies symptoms in some individuals. 4, 5 Data to support this statement consist of ocular complaints that mirror neuropathic pain elsewhere in the body, including spontaneous pain, dissociation between symptoms and peripheral findings, characterizing ocular dysesthesias as "hot burning," and sensitivity to light and wind (which can be construed as allodynia and hyperalgesia, respectively). 6 Furthermore, others and we have previously shown that DE symptoms are often found in the setting of systemic comorbidities, such as chronic widespread musculoskeletal pain, chronic pelvic pain, migraine, irritable bowel syndrome, and other chronic pain conditions, [7] [8] [9] [10] and their coexistence has been termed "chronic overlapping pain conditions." [11] [12] [13] Chronic overlapping pain conditions are also associated with other comorbidities including mood disorders, insomnia symptoms (difficulty with falling asleep, staying asleep, or with premature awakenings), and decreased quality of life. 14, 15 Many studies have previously focused on the link between DE and mental health, demonstrating that DE symptoms correlated with anxiety and depression more strongly than they did with tear film findings. 16220 Less data, however, is available on associations between DE symptoms and insomnia, while adjusting for potential confounders. [21] [22] [23] One population-based Korean study found an increased risk of DE in those with mild and severe sleep disturbances, as compared with a control group with optimal sleep (6-8 hours/day). 23 Another hospital-based Japanese study found a positive correlation between Pittsburgh Sleep Quality Index scores and DE severity. 21 In this study, we aimed to reevaluate the latter association in a unique, predominately male, U.S.-based population with a balanced racial and ethnic profile. We hypothesized that DE symptom severity and specific ocular pain complaints would be associated with clinically significant insomnia, after adjusting for demographics, depression, posttraumatic stress disorder (PTSD), and other medical comorbidities.
METHODS

Study Population
Patients with otherwise healthy eyelid and corneal anatomy were prospectively recruited from the Miami Veterans Affairs (VA) Healthcare System eye clinic from October 2013 to February 2016. Patients with a history of contact lens use; any history of refractive, glaucoma, or retina surgery; cataract surgery within the preceding 6 months; any use of ocular medications other than artificial tears; and medical history of human immunodeficiency virus, sarcoidosis, graft-versus-host disease, or collagen vascular diseases were excluded. All patients signed an informed consent form before beginning study activities. The study was conducted in accordance to the principles of the Declaration of Helsinki, complied with the requirements of the United States Health Insurance Portability and Accountability Act, and was approved by the Miami VA Institutional Review Board.
Data Collected
For each individual, demographic information, ocular and medical history, and medication information were collected through self-report structured questionnaire and confirmed through the medical record. The Charlson comorbidity weighted index was calculated based on review of the medical record. 24 Mental health status was assessed using the patient health questionnaire (PHQ-9) for depression, 25 the PTSD questionnaire (PTSD ChecklistMilitary Version) 26 for PTSD, and the symptom check list-90 for anxiety. 27 Diagnosis of obstructive sleep apnea (OSA) was determined by self-report and review of medical record.
Dry Eye Symptoms
Patients filled out standardized questionnaires regarding DE symptoms: the DE questionnaire 5 (DEQ5) 28 and the ocular surface disease index (OSDI). 29 A cutoff of 6 or greater on the DEQ5 was used to define a sample of patients with mild or greater DE symptoms and those with DEQ5 scores ,6 were considered controls free of DE symptoms. 28 
Ocular Pain Complaints
An 11-point numerical rating scale was used to assess ocular pain intensity ("How would you describe the overall intensity of your eye pain, on average during the last week?), anchored at 0 for no ocular pain and at 10 for the most intense ocular pain imaginable. Based on prior data, three additional ocular pain complaints were assessed 30 : (1) presence of spontaneous burning ocular pain and presence of evoked pain, that is, ocular pain caused or increased by (2) wind and (3) light (all rated on a scale from 0 to 10). Using responses from these three questions, we divided our sample into two groups by cluster analysis. The clustering method used was two-step cluster analysis (v22; IBM SPSS, Chicago, IL). Briefly, in step one, the procedure produces a cluster features tree, in which every case is added to an existing node of the tree or becomes a new node based on its log-likelihood distance from previously created nodes, given the variables used for clustering. In the second step, nodes of the tree are agglomeratively formed into clusters. In this step, the program uses Schwarz's Bayesian Information Criterion to select the best number of clusters (#15). The two generated groups were significantly different from each other regarding both "traditional" DE symptoms (DEQ5, OSDI) and ocular pain complaints (burning pain, sensitivity to wind and light) ( Table 1 ). Because we wish to base our classification of these patients on just three variables, which have proved important in previous studies, 10,30,31 we did not perform dimensional reduction with factor analysis/principal components. Furthermore, keeping these variables in their original units will aid our interpretation of the clusters. This division resulted in three groups of patients: (1) those with DE symptoms (DEQ5$6) and high ocular pain (HOP) complaints; (2) those with DE symptoms (DEQ5$6) and low ocular pain (LOP) complaints; and (3) controls without DE symptoms (DEQ5,6). Of note, none of the control patients experienced ocular pain complaints. Subsequent analysis was performed based on these three patients groups.
Ocular Surface Evaluation
All patients underwent tear film assessment, including measurement of (1) tear osmolarity (TearLAB, San Diego, CA) (once in each eye), (2) tear breakup time (5 mL fluorescein placed, 3 measurements taken in each eye and averaged), (3) corneal epithelial cell disruption measured by means of corneal staining (National Eye Institute) scale, 32 5 areas of cornea assessed (score 0-3 in each, total 15), (4) tear production (10 mL of anesthesia placed in the inferior fornix of each eye followed by Schirmer strips that were left in place for 5 min), and (5) meibomian gland assessment. Eyelid vascularity was graded on a scale of 0 to 3 (0, none; 1, mild engorgement; 2, moderate engorgement; 3, severe engorgement) and meibum quality on a scale of 0 to 4 (0¼clear; 1¼cloudy; 2¼granular; 3¼toothpaste; 4¼no meibum extracted).
Insomnia Severity Index
Our primary outcome was the insomnia severity index, a brief, seven-item instrument measuring the patient's perception of his or her insomnia. The first three items assess the severity of sleep-onset and sleep maintenance difficulties and difficulties with premature early awakenings, respectively. The last four items evaluate satisfaction with current sleep pattern, interference with daily functioning, observing impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. The total scores range from 0 to 28, with a cutoff score of 15 suggestive of clinically significant insomnia. 33 Its internal consistency, concurrent validity, and sensitivity to clinical improvements are well established. 33 
Statistical Analysis
Data were entered into a standardized database. Statistical analyses were performed using SPSS 22.0 (SPSS, Inc., Chicago, IL) statistical package. Analysis of variance and chi-square tests were used, as appropriate, to compare insomnia profiles between DE groups. Correlations of DE and insomnia symptoms were examined with Pearson r and Spearman rho analyses. We elected to give information on both correlations as the Pearson correlation coefficient has the intuitive interpretation as a percentage of variance explained while the Spearman correlation is sensitive to nonlinear monotonic trends and resistant to undue influence by outliers. A multivariable analysis was performed to assess the relationship between DE symptoms and insomnia, while controlling for potential confounders. Covariates (age, gender, self-reported race, and medical and psychiatric comorbidities) for insomnia were based on prior epidemiologic research. 34 A P value of ,0.05 was deemed significant.
RESULTS
Demographics and Comorbidities by DE Subgroup
One hundred eighty-seven veterans participated in the study (mean age, 63 years; 93% men). Full demographic characteristics of the study sample, grouped by no DE and DE with LOP and HOP complaints, are presented in Table 1 . All groups predominantly included male participants with comparable demographics. Individual and weighted medical comorbidities were likewise similar between the groups with the exception of diabetes mellitus, which was more frequent in the LOP group (37%) compared with the HOP group (16%) and the no DE group (18%) (P¼0.02). Mental health indices and medication profiles, on the other hand, were different between the groups. Patients in the HOP group experienced higher depression, PTSD, and anxiety scores than those in the LOP and control groups. Similarly, individuals in the HOP group were more frequently prescribed anxiolytics (57%), antidepressants (55%), and analgesics (82%) compared with those in the LOP and the control groups (P,0.05 for all).
Insomnia Symptoms by DE Subgroup Classification
All individual ISI endpoints (mean) were higher in the HOP group compared with the LOP and control groups, with significant differences between the groups with regards to most insomnia metrics (Table 2) . Of note, clinically significant insomnia (total score of $15) was found in most individuals (61%) in the HOP group but in lower frequencies in the LOP (41%) and control (18%) groups (P,0.0005; Fig. 1 ). 13 (27) 18 (17) 7 ( Questions from neuropathic pain symptom inventory, modified for the eye. Signs from more severely affected eye.
BPH, benign prostatic hypertrophy; n, number in each group; DE, dry eye; NRS, numerical rating scale for eye pain; PHQ-9, patient health questionnaire 9; PTSD, posttraumatic stress disorder; SD, standard deviation.
Correlations Between Insomnia and Symptoms and Signs of DE
All subjective metrics including "traditional" DE symptoms and ocular pain complaints significantly and positively correlated with insomnia (ISI total score) (Fig. 2) . Most ocular surface findings, on the other hand, displayed no relationship with insomnia ( Figs. 3  and 4) , with the exception of abnormal eyelid vascularity, which was found to be associated with less insomnia ( 
DISCUSSION
To conclude, we found that both DE symptoms and ocular pain complaints positively correlated with insomnia. Our data are in accordance with those of Ayaki et al. 21 who reported that DE severity correlated with the Pittsburgh Sleep Quality Index, 35 an instrument that primarily measures insomnia. Similar to this study where more than half of their eye clinic sample reported poor sleep quality, more than 60% of our patients with DE and ocular pain fulfilled insomnia syndrome criteria. Our data extend prior findings by adjusting not only for demographic and ophthalmologic factors but also for important medical and mental health comorbidities in a novel sample of U.S. military veterans.
We chose the ISI as our metric for insomnia to allow comparisons with other chronic pain populations. For example, our finding that 61% of individuals with HOP experienced clinically significant insomnia is similar in proportion to that found in other chronic pain groups, including a musculoskeletal ISI, insomnia severity index; SD, standard deviation.
FIG. 1.
Higher mean insomnia scores in those with dry eye symptoms and high ocular pain as compared with those with dry eye symptoms and low ocular pain and those without dry eye symptoms (controls).
FIG. 2.
Positive relationship between dry eye symptoms (dry eye questionnaire 5 score) and insomnia (insomnia severity index score).
pain population 36 and a Veterans Affairs Medical Center Polytrauma Clinic 37 (;70% ISI scores, $15). In a similar manner, our correlation coefficient of 0.39 between average ocular pain intensity and insomnia is similar to that reported between pain and insomnia in other populations including those with depression (0.24-0.30), 38 chronic neck pain (0.35), 39 and chronic back pain (0.26). 40 Our noted association between DE and insomnia has many potential explanations. First, it is possible that DE symptoms and ocular pain may precipitate insomnia. As individuals predisposed to insomnia can have excessive preoccupation with events surrounding sleep and heightened cognitive responses to stressful situations, 41 nocturnal eye discomfort may be more distressful and prominent among these individuals than among healthy sleepers. 21 Thus, as has been demonstrated in other pain conditions, 42 eye discomfort and its associated psychological distress 43 may interfere with sleep initiation. After the acute onset of insomnia, patients may develop maladaptive behavioral strategies (i.e., daytime napping, spending excessive amounts of time in bed) and dysfunctional sleep beliefs in an attempt to cope with sleep difficulties. 44 Over time, insomnia can become entrenched by these psychological and behavioral changes and becomes more challenging to reverse. 45 In relation to DE, patients with newly diagnosed DE were found to have greater improvement in sleep after initiation of topical DE therapy compared with those with long-standing DE, 22 the latter of which may have had more chronically entrenched insomnia.
Second, it is possible that insomnia leads to changes in tear physiology and DE symptoms. Studies have found that tear physiology differs during sleep (when the eye is closed) and waking (when the eye is blinking). 46 During sleep, changes in lacrimation (slower, constitutive secretion), protein composition (mostly secretory immunoglobulin A), and inflammation (buildup and activation of complement and proinflammatory soluble and cellular mediators) have been described. Insomnia likely has an effect on the tear physiology, as sleep deprivation in healthy individuals has been associated with reduced tear secretion and tear hyperosmolarity. 47 In animal models, parasympathetic tone decreases in sleep disruption, which could contribute to decreased nocturnal tear production by means of lower lacrimal gland activity. 48 Thus, individuals with insomnia with recurrent nocturnal arousals or curtailed sleep may exhibit a change in their tear film physiology with resultant eye irritation and dryness.
Yet, a third possibility is that the association between DE and insomnia may be indirect and driven by underlying factors, such as shared psychological profiles, genetic susceptibility, or somatosensory dysfunction. Regarding psychological profiles, insomnia and DE are both highly comorbid with depression and anxiety All numbers represent the more severe value in either eye. a P,0.01.
DEQ5, dry eye questionnaire; OSDI, ocular surface disease index questionnaire.
FIG. 3.
No relationship between tear breakup time and insomnia (insomnia severity index score).
FIG. 4.
No relationship between tear production (Schirmer score) and insomnia (insomnia severity index score).
symptoms. 17, 41, 45, 49 Genetic polymorphisms, such as in proinflammatory genes, may underlie the associations between DE, insomnia, and depression. 50, 51 Interestingly, proinflammatory gene polymorphisms in interleukin (IL)-1beta and IL-6 receptor have been associated with DE symptoms in Korean population. 52 Such polymorphisms may underlie the pathologic elevation of proinflammatory cytokines, including tumor necrosis factor-alpha, IL-6, and IL-1b, that have been found in the tears of DE patients and blood of patients with depression and insomnia. [53] [54] [55] [56] [57] Proinflammatory cytokines can mediate pain syndromes and insomnia through numerous mechanisms, including increased spontaneous firing of neurons, 58 enhanced excitatory neurotransmission through neuralglial interactions, and phenotypic alterations of primary afferents. 59 Directionality between sleep and pain has been studied in other models. Although this relationship was initially described as reciprocal and bidirectional, recent longitudinal studies suggest that sleeping disturbances are a stronger predictor of pain than pain of sleeping disturbances. 60 For example, in a study of polyarticular arthritis, daily reports of poor sleep quality predicted daily pain, but the reverse association was not significant. 61 Self-reported and experimental sleep continuity disturbances in fibromyalgia, rheumatoid arthritis, and temporomandibular disorder have all been associated with diminished conditioned pain modulation, a measure of endogenous opioid-mediated pain inhibition. [62] [63] [64] Thus, this suggests that insomnia may promote pain entrenchment by impairment in the descending pain modulatory systems.
As with all studies, our study has limitations, which must be considered when interpreting the study results. First, our crosssectional design precludes the determination of whether insomnia preceded or followed the onset of subjective DE symptoms. Second, the current study sample consisted of U.S. veterans, most of whom are older male individuals. Although this provides contrast to several other studies examining female DE patients 8, 65 and the Asian studies examining DE and sleep, [21] [22] [23] its results may not be generalized to other populations. Third, all our measurements were obtained using specific scales and techniques. We chose the ISI because it is a well-validated instrument used in community-based and clinical samples. 33, 66, 67 Fourth, many factors can underlie insomnia, and it is impossible to control for all potential confounders, including comorbidities (depression, PTSD), medications, and the complex interaction between DE signs and symptoms. Finally, our diagnosis of OSA was self-reported and not verified with a sleep study. The presence of OSA may be a confounder for the noted association between DE symptoms and insomnia. 68 Despite these limitations, this study is important because it highlights that patients with DE symptoms may have comorbidities, such as insomnia, that need to be evaluated and addressed using a multidisciplinary approach. It is not yet known, however, whether improvement in DE symptoms will improve systemic parameters or, conversely, if treatment of nonocular pain, depression, anxiety, and disturbed sleep will in turn improve DE symptoms. This is an important avenue of future longitudinal studies.
